On August 13, 2024, VitaVitro Biotech received notification from the National Unified Procurement Company for Medical Supplies (NUPCO) of the Ministry of Health of the Kingdom of Saudi Arabia, confirming the company’s successful bid for the 2025-2027 public reproductive centre procurement project. This achievement marks an important breakthrough for VitaVitro in the high-end international healthcare market in the Middle East, further enhancing the company's leading position in the global market.
Comprehensive Product Line Awarded
The awarded product line covers 12 major categories and 21 sub-categories of laboratory reagents and consumables for reproductive centres, demonstrating the extensive applicability and outstanding quality of VitaVitro’s products. Of particular note is that VitaVitro's vitrification and thawing solutions have been selected as exclusive products, positioning the company as the designated brand for the freezing and thawing processes in Saudi public reproductive centres for the next three years.
Saudi Arabia’s NUPCO public procurement system is renowned for its stringent evaluation criteria. In addition, the country has extremely rigorous registration requirements for medical devices, which include compliance with both European and American product certifications as well as local high standards. As the only Chinese brand to secure this bid, VitaVitro’s successful entry into the Saudi market highlights the technological and quality excellence of its products and underscores the company’s competitiveness and brand influence on the international stage.
This milestone marks a key step in VitaVitro’s internationalisation strategy. After years of cultivating its presence in the global market, the company will continue to adhere to the philosophy of "innovation-driven, service-first" to enhance its product technology and service systems, providing high-quality, integrated solutions to reproductive centres worldwide.